NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

惡性間皮癌的全球市場

Malignant Mesothelioma

出版商 Global Industry Analysts, Inc. 商品編碼 997506
出版日期 內容資訊 英文 139 Pages
商品交期: 最快1-2個工作天內
價格
惡性間皮癌的全球市場 Malignant Mesothelioma
出版日期: 2021年04月01日內容資訊: 英文 139 Pages
簡介

全球惡性間皮癌的市場規模,預計在分析期間(2020年∼2027年)將以6.1%的年複合成長率增長,從2020年的3億7,920萬美元,到2027年達到5億7,460萬美元。

本報告提供全球惡性間皮癌市場的相關調查,提供市場佔有率,Covid-19的影響,趨勢和成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Concordia International Corporation
  • Corden Pharma International GmbH
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi AG
  • Kyowa Hakko Kirin Co., Ltd.
  • Merck & Co., Inc.
  • MolMed S.p.A.
  • Mylan NV
  • Nichi-Iko Pharmaceutical Co., Ltd.
  • Novartis International AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Polaris Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

目錄

I. 調查手法

II. 摘要整理

  • 市場概要
    • 影響者市場洞察
    • 全球市場的軌跡
    • Covid-19的影響與即將到來的全球景氣衰退
  • 主要企業
  • 趨勢與推動要素
  • 全球市場預測

III. 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 其他地區

IV. 競爭

  • 企業簡介:43公司

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP13152

Abstract:

Global Malignant Mesothelioma Market to Reach $574.6 Million by 2027

Amid the COVID-19 crisis, the global market for Malignant Mesothelioma estimated at US$379.2 Million in the year 2020, is projected to reach a revised size of US$574.6 Million by 2027, growing at a CAGR of 6.1% over the analysis period 2020-2027. Premetrexed and combination, one of the segments analyzed in the report, is projected to record a 6.7% CAGR and reach US$302.7 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Cisplatin and combination segment is readjusted to a revised 6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $112 Million, While China is Forecast to Grow at 5.7% CAGR

The Malignant Mesothelioma market in the U.S. is estimated at US$112 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$100.7 Million by the year 2027 trailing a CAGR of 5.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.8% and 4.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Carboplatin and combination Segment to Record 5.7% CAGR

In the global Carboplatin and combination segment, USA, Canada, Japan, China and Europe will drive the 5.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$40.4 Million in the year 2020 will reach a projected size of US$59.8 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$65.9 Million by the year 2027.

Select Competitors (Total 43 Featured) -

  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Concordia International Corporation
  • Corden Pharma International GmbH
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi AG
  • Kyowa Hakko Kirin Co., Ltd.
  • Merck & Co., Inc.
  • MolMed S.p.A.
  • Mylan NV
  • Nichi-Iko Pharmaceutical Co., Ltd.
  • Novartis International AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Polaris Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Malignant Mesothelioma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Malignant Mesothelioma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Malignant Mesothelioma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Premetrexed and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Premetrexed and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Premetrexed and combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Cisplatin and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Cisplatin and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Cisplatin and combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Carboplatin and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Carboplatin and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Carboplatin and combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Gemcitabine and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Gemcitabine and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Gemcitabine and combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Vinorelbine and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Vinorelbine and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Vinorelbine and combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Other Combinations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Other Combinations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Other Combinations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 22: USA Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 23: USA Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 24: USA 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 25: Canada Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 26: Canada Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 27: Canada 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 28: Japan Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 29: Japan Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 30: Japan 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 31: China Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 32: China Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 33: China 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 34: Europe Current & Future Analysis for Malignant Mesothelioma by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 35: Europe Historic Review for Malignant Mesothelioma by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 36: Europe 15-Year Perspective for Malignant Mesothelioma by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 37: Europe Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Europe Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 39: Europe 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 40: France Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 41: France Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 42: France 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 43: Germany Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Germany Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 45: Germany 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 46: Italy Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Italy Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 48: Italy 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 49: UK Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: UK Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 51: UK 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 52: Rest of Europe Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Rest of Europe Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 54: Rest of Europe 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 55: Asia-Pacific Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Asia-Pacific Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 57: Asia-Pacific 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 58: Rest of World Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Rest of World Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 60: Rest of World 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 43